31. An isolated polynucleotide encoding the ABM or antibody of any of claims 1-30.

32. A vector comprising the polynucleotide of claim 31.

33. A host cell comprising the vector of claim 32.

34. A composition comprising the ABM or antibody of any of claims 1-30 and a pharmaceutically acceptable carrier.

35. An *in vitro* method of inducing cell lysis of a tumor cell, the method comprising contacting the tumor cell with the ABM or antibody of any of claims 1-30 or the composition of claim 34.

36. The *in vitro* method of claim 35, wherein the tumor cell is selected from the group consisting of a colorectal cancer cell, NSCLC (non-small cell lung cancer), gastric cancer cell, pancreatic cancer cell and breast cancer cell.

37. The *in vitro* method of claim 35, wherein the cell lysis is induced by antibody dependent cell cytotoxicity of the ABM or antibody.

38. ~~A method of treating a subject having a cancer that abnormally expresses CEA, the method comprising administering to the subject a therapeutically effective amount of the~~ The ABM or antibody of any one of claims 1-30 or the composition of claim 34 for use in treating a subject having a cancer that abnormally expresses CEA.

39. ~~A method of increasing survival time in a subject having a cancer that abnormally expresses CEA, the method comprising administering to the subject a therapeutically effective amount of the~~ The ABM or antibody of any one of claims 1-30 or the composition of claim 34 for use in increasing survival time in a subject having a cancer that abnormally expresses CEA.

40. The ABM, antibody or composition ~~method~~ of claim 38 or 39, wherein the cancer is selected from the group consisting of colorectal cancer, non-small cell lung cancer (NSCLC), gastric cancer, pancreatic cancer and breast cancer.

41. The ABM, antibody or composition of any of claims 35-40, wherein the ABM or antibody or composition is for administration ~~administered~~ in combination with chemotherapy or radiation therapy.

42. The ABM, antibody or composition ~~method~~ of any of claims 35-41, wherein the subject is a human.

43. Use of the ABM or antibody of any of claims 1-30 or the composition of claim 34 in the manufacture of a medicament for treating a subject having a cancer that abnormally expresses CEA.

44. The use of claim 43, wherein the cancer is selected from the group consisting of colorectal cancer, non-small cell lung cancer (NSCLC), gastric cancer, pancreatic cancer and breast cancer.